Board summary
Key figures
53,475
Registered population
51.8% aged 18–64
34.0%
Aged 65+
ICB 20.0% · England 17.9%
3.7%
Ethnic minority (non-White)
1.4% Asian · England 9.6%
7.7%
In IMD quintile 1
ICB 30.6% · England 21.0%
~5,566
Core20 residents (est.)
Resident basis; registered basis ~4,360 · see page 3
12,701
Hypertension register
+10.15% in 3 yrs · England +5.60%
715
SMI register
73.8% of Fylde's
1,491
COPD register
Reviews +3.31% in 3 yrs
Forecast to 2030
16,132
Hypertension patients, 2030
+3,431 on today
61.9%
QRISK ≥20% on statins, 2030
+2.74pp over 3 yrs
8.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Core20 deprivation is concentrated in two practices.
Practice Core20 shares span 19.4 pp: Parcliffe Medical Centre and Poplar House Surgery are at 19.4%, whereas Holland House Surgery and Fernbank Surgery are.
Lipid therapy and asthma reviews trail England.
Asthma review coverage is 63.5% (England 65.7%; 1,368 unreviewed) and QRISK ≥ 20% lipid therapy is 56.0% (England 63.6%), which may reflect unverified recall.
Diabetes and hypertension control exceed national benchmarks.
Diabetes HbA1c control without frailty reaches 64.3% (England 57.4%, ICB 56.2%) and hypertension treatment to target is 71.3% (England 70.3%, Fylde 69.7%).
Population, age and ethnicity
Patients aged 65+ make up 34.0% of the list, exceeding England's 17.9%
Across the PCN, 53,475 patients are registered. Patients aged 65+ account for 34.0% (18,166 patients), above Fylde (29.0%), the ICB (20.0%) and England (17.9%), while 14.3% are aged 0–17 (Fylde 15.6%, ICB 19.6%, England 19.6%). In Census resident data, 96.3% identify as White (Fylde 96.3%, ICB 87.8%, England 81.1%) and 3.7% from ethnic minority backgrounds, including 1.4% Asian / Asian British (Fylde 1.4%, ICB 9.4%, England 9.6%). Ethnicity reflects Census usual residents rather than registered patients.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Fylde local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Fylde LA) | 1,531 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 64.3% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Fylde LA) | 782 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Fylde LA) | 15.4 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 7.7% overall but spans 19.4 percentage points between practices
The PCN Core20 share is 7.7%, above Fylde (5.1%) but below the ICB (30.6%) and England (21.0%), with an estimated 5,566 resident Core20 population across IMD deciles 1 and 2. Practice shares span 19.4 percentage points: Parcliffe Medical Centre is at 19.4% (2,341 estimated patients) and Poplar House Surgery is at 19.4% (1,287 estimated patients), while Holland House Surgery and Fernbank Surgery record 0.0%. Reconciling practice registered totals (4,360) against resident estimates (5,566) will clarify outreach scale across the two concentrated practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
715
SMI register
1.33% recorded prevalence
294
Learning disability register
0.55% recorded prevalence
36
Care homes, 1,195 beds
In the PCN catchment
9.5%
Provide unpaid care
Fylde, Census 2021
Recorded severe mental illness prevalence is 1.3% (715 patients; Fylde 1.3%, ICB 1.2%, England 1.0%), while learning disability prevalence is 0.6% (294 patients; Fylde 0.5%, ICB 0.6%, England 0.6%). The PCN catchment also encompasses 36 care homes with 1,195 beds. Care home bed capacity and recorded registers reflect catchment scale, though bed counts do not establish resident occupancy or registered patient use.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.3% (715 patients). Twelve-month blood pressure recording is 79.8% (England 83.4%), BMI recording is 77.2% (England 82.1%) and alcohol recording is 75.7% (England 81.8%), which may reflect recall gaps that audit would test.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
12,701
Hypertension register
+10.15%
Register growth, 3 yrs
Fylde +9.01% · England +5.60%
+1.41pp
BP control, under 80
≤140/90 · +2.73pp aged 80+
+3,431
More patients by 2030
Forecast 16,132 (28.65%)
Hypertension case-finding and control
Hypertension register prevalence is 23.6% (12,701 patients), above Fylde (21.9%), the ICB (17.2%) and England (15.2%), consistent with an older demographic (34.0% aged 65+ vs England 17.9%). Over 2023 to 2025, the register rose 10.2% (England +5.6%). Blood pressure control in patients aged under 80 reaches 67.5%, above Fylde (66.2%) and the ICB (67.1%) but trailing England (67.8%), with three-year progress (+1.4 pp) behind England (+2.1 pp). Observation periods for current counts were not supplied. Trailing national blood pressure control for under-80s indicates a priority to review recall and treatment titration.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy reaches 56.0%, trailing England (63.6%), the ICB (61.4%) and Fylde (56.5%). Lower uptake than England indicates a gap in primary prevention treatment.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 148,735 | £1.40 | £1.64 | £1.86 | £208,229 |
| Cardiovascular (all), 2025 | 230,220 | £3.39 | £3.38 | £3.33 | £780,446 |
In 2026, the PCN prescribed 148,735 items of lipid-regulating drugs at £1.40 per item, above Fylde (£1.26) but below the ICB (£1.64) and England (£1.86), spending £68,418 less than at England's unit cost across these items. Lower unit costs reflect item expenditure rather than prescribing efficiency or treatment appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+4.90%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.19%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.2% (3,746 patients; England 6.6%), but 12-month review coverage is 63.5%, trailing England (65.7%) and the ICB (65.0%), leaving an estimated 1,368 patients unreviewed. Asthma management items prescribed per 1000 5-19 Population are 2,000 rate (England 1,488 rate). COPD prevalence is 2.8% (1,491 patients; England 1.9%), with reviews at 78.1% (England 76.4%). Lower asthma review coverage could reflect recall shortfalls, which clinical audit would test.
Cancer register and children's immunisation
Cancer prevalence is 6.8% (3,669 patients; England 3.8%). In Q1 2025/26 childhood immunisations, 12-month 6-in-1 coverage is 98.9%, exceeding the 95.0% target. At age 5, MMR dose 2 and 4-in-1 booster coverage are both 91.9%, falling below the 95.0% target by 3.1 pp, while MMR dose 1 is 94.6% (a 2.7 pp difference). Slower booster uptake could reflect recall timing gaps, which scheduling audit would test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of staged cancers in NHS Lancashire and South Cumbria ICB were diagnosed at stage 1 or 2 (4,642 of 8,863 known-stage cases), below England (55.3%) and 22.6 pp below the 75.0% national ambition for 2028. Staged share was 74.6% (8,863 of 11,883; England 67.0%). Early detection was lower in lung (31.1% vs England 33.8%) and bowel (44.2% vs England 47.0%), but higher in breast (86.0% vs England 85.4%). Reaching 75.0% requires about 2,010 additional early diagnoses across the ICB. Staged coverage and small site cohorts warrant caution; these system figures do not establish PCN performance. ICB early-stage shortfalls reinforce the need for robust primary care safety-netting.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional Jul 2026 data, Blackpool Teaching Hospitals NHS Foundation Trust achieved 98.0% on the 31-day cancer standard (standard 96.0%; ICB 93.6%, England 92.5%). However, the 62-day referral standard was 67.5% (standard 85.0%), trailing Lancashire Teaching Hospitals NHS Foundation Trust (75.0%), the ICB (73.6%) and England (71.2%). The 28-day faster diagnosis standard was 71.4% (standard 75.0%; Lancashire Teaching Hospitals 82.9%, England 79.3%). In diagnostics, 6+ week waits reached 21.8% for MRI and 16.5% for CT (England 9.9%). Provider data reflects acute capacity, not PCN delivery. Local acute diagnostic and 62-day delays may prolong time to confirmed cancer treatment.
| Pathways within standard (%) | Blackpool | Lancashire | Liverpool | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.38 | 82.90 | 75.47 | 78.39 | 79.32 |
| 31-day treatment (96%) | 97.96 | 89.43 | 90.51 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 67.48 | 75.04 | 73.26 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Blackpool | Lancashire | Liverpool | England |
|---|---|---|---|---|
| MRI | 21.80 | 2.41 | 6.42 | 21.40 |
| CT | 16.49 | 14.97 | 0.71 | 9.92 |
| Echocardiography | 7.57 | 13.85 | 12.55 | 28.48 |
| Colonoscopy | 13.08 | 0.00 | 33.14 | 30.83 |
| Gastroscopy | 12.47 | 0.00 | 44.99 | 29.02 |
| All 15 DM01 tests | 26.54 | 26.65 | 11.50 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In provisional Jun 2026 Community Services Dataset records, Fylde borough residents had 126,445 community service contacts, of which 72,000 (56.9%) were with adults aged 65+. These figures represent borough resident activity rather than provider or PCN caseloads. High community contact volumes among older adults indicate substantial local demand for integrated multidisciplinary and intermediate care.
Practice variation and patient experience
Vaccination and immunisation achievement varies across practices by 49.1 pp
In 2025/26, England overall QOF achievement was 92.5%. Poplar House Surgery achieved 87.1% overall achievement, and Holland House Surgery achieved 97.3%. In the vaccination and immunisation domain, Poplar House Surgery achieved 33.4%, whereas Fernbank Surgery achieved 82.5% (England comparator 55.2%), with a practice range of 49.1 pp between Poplar House Surgery and Fernbank Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Ansdell | 111 | 5.7 | 45.6% | 65.8% | 75.5% |
| Parcliffe | 112 | 19.4 | 42.6% | 73.8% | 73.2% |
| Fernbank Surgery | 113 | 0.0 | 48.6% | 69.0% | 72.9% |
| Holland House | 114 | 0.0 | 42.3% | 57.2% | 70.8% |
| Poplar House | 118 | 19.4 | 42.8% | 58.6% | 63.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Smoking cessation offers fell 3.1 pp, trailing England by 3.2 percentage points
Over 2023 to 2025, smoking cessation support fell 3.1 pp (England +0.1 pp), and SMI BMI recording rose 2.1 pp, trailing England's +5.1 pp gain. COPD prevalence contracted 2.4% over three years (England +2.6%), though current prevalence remains 2.8% (England 1.9%). Conversely, heart failure reviews rose 24.8% (England +8.7%) to reach 81.8% (England 78.5%), and diabetes HbA1c control without frailty expanded 8.0% (England +4.4%) to 64.3% (England 57.4%). Slower progress could reflect recall or coding gaps, which local audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD register
Smoking support (SMI)
BMI record (SMI)
Learning disability register
Hypertension treated to target
Heart failure reviews
Diabetes HbA1c control
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Fylde | Asset | PCN | Fylde |
|---|---|---|---|---|---|
| Care homes (catchment) | 36 (1,195 beds) | n/a | Schools (catchment) | 29 | n/a |
| Children's centres | 3 | 5 | Places of worship | 38 | 54 |
| Libraries | 3 | 4 | Primary schools (LA maintained) | 8 | 15 |
| Primary academies | 3 | 5 | Special schools | 2 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
On the 3,746 asthma register, 12-month review coverage is 63.5%, below England (65.7%) and the ICB (65.0%), leaving an estimated 1,368 patients unreviewed. For discussion: the PCN could run structured recall using a single review template alongside inhaler prescribing checks and flexible appointment slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Two-list Core20 and lipid review
QRISK ≥ 20% lipid therapy is 56.0% (England 63.6%, ICB 61.4%). Core20 share is 7.7% (England 21.0%) but spans 19.4 pp, reaching 19.4% at Parcliffe Medical Centre (2,341 estimated patients) and Poplar House Surgery (1,287). Moderate effort to run.
Evidence base: the share of patients in the most deprived quintile is the Core20 targeting measure used to weight inequalities funding, outreach and prevention capacity, and the gradient every clinical indicator should be read against.
Policy anchor: Core20PLUS5 (Core20 = the most deprived 20% by IMD); 10 Year Health Plan, with widening inequalities the equity test of reform.
Option 3
Learning disability register validation
Learning disability QOF prevalence is 0.6% (294 patients; England 0.6%, Fylde 0.5%, list 53,475), with 2023 to 2025 growth (+3.5%) trailing England (+5.4%) and Fylde (+6.0%). For discussion: practices could validate diagnostic codes and cross-check lists with local authority social-care records where information-sharing agreements exist. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted deprivation outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure recall (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Early presentation and referral audit (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Two-list Core20 and lipid review (p12) | Core20 cohort (IMD quintile 1) · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 · 10YHP equity test · Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
